Cargando…

The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)

OBJECTIVE: Evidence that midregional fragment of pro-A–type natriuretic peptide (MR-proANP) is a marker of mortality in patients with type 2 diabetes is limited. Therefore, we aimed to investigate the capabilities of MR-proANP in predicting mortality. We also investigated whether MR-proANP influence...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hateren, Kornelis J.J., Landman, Gijs W.D., Kleefstra, Nanne, Groenier, Klaas H., Struck, Joachim, Navis, Gerjan J., Bakker, Stephan J.L., Houweling, Sebastiaan T., van der Meer, Klaas, Bilo, Henk J.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631859/
https://www.ncbi.nlm.nih.gov/pubmed/23230100
http://dx.doi.org/10.2337/dc12-0428
_version_ 1782266818447015936
author van Hateren, Kornelis J.J.
Landman, Gijs W.D.
Kleefstra, Nanne
Groenier, Klaas H.
Struck, Joachim
Navis, Gerjan J.
Bakker, Stephan J.L.
Houweling, Sebastiaan T.
van der Meer, Klaas
Bilo, Henk J.G.
author_facet van Hateren, Kornelis J.J.
Landman, Gijs W.D.
Kleefstra, Nanne
Groenier, Klaas H.
Struck, Joachim
Navis, Gerjan J.
Bakker, Stephan J.L.
Houweling, Sebastiaan T.
van der Meer, Klaas
Bilo, Henk J.G.
author_sort van Hateren, Kornelis J.J.
collection PubMed
description OBJECTIVE: Evidence that midregional fragment of pro-A–type natriuretic peptide (MR-proANP) is a marker of mortality in patients with type 2 diabetes is limited. Therefore, we aimed to investigate the capabilities of MR-proANP in predicting mortality. We also investigated whether MR-proANP influences the relationship between blood pressure and mortality in old age. RESEARCH DESIGN AND METHODS: In 1998, 1,143 primary care patients with type 2 diabetes participated in the ZODIAC study. Because blood was drawn for 867 patients (76%) and confounders were missing for 19 patients, the final study sample comprised 848 patients. After a follow-up time of 10 years, we used Cox proportional hazard models to evaluate the relationship between MR-proANP and (cardiovascular) mortality. Harrell C statistic was used to compare models with and without MR-proANP. The regression analyses were repeated without MR-proANP for patients aged older than 75 years. RESULTS: Median MR-proANP in the total study sample was 75 pmol/L (interquartile range, 48–124 pmol/L). During follow-up, 354 (42%) out of 848 patients had died, of whom 152 (43%) deaths were attributable to cardiovascular factors. MR-proANP was independently associated with all-cause and cardiovascular mortality, irrespective of age. During old age, there was a significant inverse relationship between blood pressure and mortality. This relationship did not change after adjustment for MR-proANP. CONCLUSIONS: MR-proANP is independently associated with mortality in patients with type 2 diabetes. MR-proANP did not influence the inverse relationship between blood pressure and mortality in elderly patients.
format Online
Article
Text
id pubmed-3631859
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-36318592014-05-01 The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25) van Hateren, Kornelis J.J. Landman, Gijs W.D. Kleefstra, Nanne Groenier, Klaas H. Struck, Joachim Navis, Gerjan J. Bakker, Stephan J.L. Houweling, Sebastiaan T. van der Meer, Klaas Bilo, Henk J.G. Diabetes Care Original Research OBJECTIVE: Evidence that midregional fragment of pro-A–type natriuretic peptide (MR-proANP) is a marker of mortality in patients with type 2 diabetes is limited. Therefore, we aimed to investigate the capabilities of MR-proANP in predicting mortality. We also investigated whether MR-proANP influences the relationship between blood pressure and mortality in old age. RESEARCH DESIGN AND METHODS: In 1998, 1,143 primary care patients with type 2 diabetes participated in the ZODIAC study. Because blood was drawn for 867 patients (76%) and confounders were missing for 19 patients, the final study sample comprised 848 patients. After a follow-up time of 10 years, we used Cox proportional hazard models to evaluate the relationship between MR-proANP and (cardiovascular) mortality. Harrell C statistic was used to compare models with and without MR-proANP. The regression analyses were repeated without MR-proANP for patients aged older than 75 years. RESULTS: Median MR-proANP in the total study sample was 75 pmol/L (interquartile range, 48–124 pmol/L). During follow-up, 354 (42%) out of 848 patients had died, of whom 152 (43%) deaths were attributable to cardiovascular factors. MR-proANP was independently associated with all-cause and cardiovascular mortality, irrespective of age. During old age, there was a significant inverse relationship between blood pressure and mortality. This relationship did not change after adjustment for MR-proANP. CONCLUSIONS: MR-proANP is independently associated with mortality in patients with type 2 diabetes. MR-proANP did not influence the inverse relationship between blood pressure and mortality in elderly patients. American Diabetes Association 2013-05 2013-04-13 /pmc/articles/PMC3631859/ /pubmed/23230100 http://dx.doi.org/10.2337/dc12-0428 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
van Hateren, Kornelis J.J.
Landman, Gijs W.D.
Kleefstra, Nanne
Groenier, Klaas H.
Struck, Joachim
Navis, Gerjan J.
Bakker, Stephan J.L.
Houweling, Sebastiaan T.
van der Meer, Klaas
Bilo, Henk J.G.
The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
title The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
title_full The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
title_fullStr The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
title_full_unstemmed The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
title_short The Midregional Fragment of Pro-A–Type Natriuretic Peptide, Blood Pressure, and Mortality in a Prospective Cohort Study of Patients With Type 2 Diabetes (ZODIAC-25)
title_sort midregional fragment of pro-a–type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (zodiac-25)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631859/
https://www.ncbi.nlm.nih.gov/pubmed/23230100
http://dx.doi.org/10.2337/dc12-0428
work_keys_str_mv AT vanhaterenkornelisjj themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT landmangijswd themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT kleefstrananne themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT groenierklaash themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT struckjoachim themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT navisgerjanj themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT bakkerstephanjl themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT houwelingsebastiaant themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT vandermeerklaas themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT bilohenkjg themidregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT vanhaterenkornelisjj midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT landmangijswd midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT kleefstrananne midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT groenierklaash midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT struckjoachim midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT navisgerjanj midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT bakkerstephanjl midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT houwelingsebastiaant midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT vandermeerklaas midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25
AT bilohenkjg midregionalfragmentofproatypenatriureticpeptidebloodpressureandmortalityinaprospectivecohortstudyofpatientswithtype2diabeteszodiac25